Zhou Yandan, Feng Zhili, Wen Jie, Yang Chi, Jing Qiancheng
Changsha Aier Eye Hospital, Aier Eye Hospital Group, Changsha, Hunan, People's Republic of China.
Department of Otolaryngology Head and Neck Surgery, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, People's Republic of China.
J Inflamm Res. 2023 Oct 25;16:4845-4855. doi: 10.2147/JIR.S432281. eCollection 2023.
Allergic rhinitis (AR) is a common allergic disease, and SLIT has shown effectiveness as a treatment method. This study focuses on the evaluation of serum TAM receptor tyrosine kinases (TYRO3, AXL, and MER) levels as potential indicators of disease severity and predictive markers for sublingual immunotherapy (SLIT) responsiveness in AR patients.
A total of 160 AR subjects, including 40 mild AR (MAR) and 120 moderate-severe AR (MSAR) patients, and 40 healthy controls (HC) were recruited. Serum concentrations of TYRO3, AXL, and MER were measured and their relationships with disease severity were examined. In the MSAR group, 102 patients underwent SLIT, and the early efficacy was evaluated. The correlations between the baseline serum concentrations of TYRO3, AXL, and MER and the early responsiveness of SLIT were analyzed.
Serum concentrations of TYRO3, AXL, and MER were significantly reduced in AR patients, particularly in those MSAR subjects. Correlation analysis results indicated that serum TYRO3 and MER levels were negatively correlated with the visual analog scale (VAS) and the total nasal symptom score (TNSS). After one year of follow-up, 80 AR patients completed the treatment and were divided into effective and ineffective groups. Serum baseline levels of TYRO3 and MER were found to be lower in the effective group compared to the ineffective group. Additionally, there was a significant increase in serum TYRO3 and MER levels compared to baseline levels. Receiver operating characteristic (ROC) analysis revealed that circulating TYRO3 and MER had potential values for reflecting AR severity and predicting early SLIT responsiveness.
Serum TYRO3 and MER concentrations were decreased in AR patients and negatively associated with disease severity. Circulating TYRO3 and MER seem to be promising indicators for monitoring the efficacy of SLIT in AR patients.
变应性鼻炎（AR）是一种常见的变应性疾病，而舌下免疫治疗（SLIT）已显示出作为一种治疗方法的有效性。本研究聚焦于评估血清TAM受体酪氨酸激酶（TYRO3、AXL和MER）水平，将其作为AR患者疾病严重程度的潜在指标以及舌下免疫治疗（SLIT）反应性的预测标志物。
共招募了160例AR受试者，包括40例轻度AR（MAR）患者和120例中重度AR（MSAR）患者，以及40例健康对照（HC）。测量了血清TYRO3、AXL和MER的浓度，并检查了它们与疾病严重程度的关系。在MSAR组中，102例患者接受了SLIT，并评估了早期疗效。分析了TYRO3、AXL和MER的基线血清浓度与SLIT早期反应性之间的相关性。
AR患者血清TYRO3、AXL和MER浓度显著降低，尤其是MSAR受试者。相关性分析结果表明，血清TYRO3和MER水平与视觉模拟量表（VAS）和总鼻症状评分（TNSS）呈负相关。随访一年后，80例AR患者完成治疗并分为有效组和无效组。发现有效组的血清TYRO3和MER基线水平低于无效组。此外，与基线水平相比，血清TYRO3和MER水平有显著升高。受试者工作特征（ROC）分析显示，循环中的TYRO3和MER在反映AR严重程度和预测SLIT早期反应性方面具有潜在价值。
AR患者血清TYRO3和MER浓度降低，且与疾病严重程度呈负相关。循环中的TYRO3和MER似乎是监测AR患者SLIT疗效的有前景的指标。
